Summary
Verapamil was evaluated as an antihypertensive agent in a pilot study. Intravenous administration of 0.1 mg/kg, followed by constant infusion of 0.0035 mg/kg/min, reduced both systolic and diastolic blood pressure significantly; the maximal average decrease of 23/16 mm Hg occurred after 5 min. The resting pulse rate rose during infusion and prolongation of the atrio-ventricular conduction time was a constant finding. After the initial drop in blood pressure, a rise toward control levels was observed, despite an increase in the infusion rate. Five patients received oral treatment with verapamil 320–640 mg daily for 7 weeks. In four of the five patients a blood pressure reduction was obtained (mean: 14/12 mm Hg), but normotension was not achieved in any of them. In contrast to the acute studies, the atrio-ventricular conduction time showed no change and a decrease in resting pulse rate was noted. Two patients experienced sensations of heat and reddening of face during treatment. It is concluded that verapamil has a rather modest antihypertensive effect and it is not suitable for the treatment of arterial hypertension.
Similar content being viewed by others
References
Bender, F.: Die Behandlung der tachycarden Arrhythmien und der arteriellen Hypertonie mit Verapamil. Arzneimittelforsch.20, 1310 (1970)
Brittinger, W.D., Schwarzbeck, A., Wittenmeier, K.W., Twittenhoff, W.D., Stegaru, B., Juber, W., Ewald, R.W., v. Henning, G.E., Fabricius, M., Strauch, M.: Klinisch-experimentelle Untersuchungen über die blutdrucksenkende Wirkung von Verapamil. Dtsch. Med. Wschr.95, 1871 (1970)
Diekmann, L., Hösemann, R.: Zur blutdrucksenkenden Wirkung von Verapamil — Untersuchungen und Erfahrungen bei Kindern. Münch. Med. Wschr.10, 515 (1974)
Ekelund, L.G., Orö. L.: Antianginal efficiency of nifedipine with and without a beta-blocker. A subacute study with exercise tests. 3rd International Adalat® Symposium, p. 218. Amsterdam: Excerpta Medica 1976
Haeusler, G.: The effect of verapamil on the contractility of smooth muscle and on the excitation-secretion coupling in adrenergic nerve terminals. Angiologica8, 156 (1971)
Krikler, D.: Verapamil in cardiology. Europ. J. Cardiol.2/1, 3 (1974)
Koch-Weser, J.: Vasodilator drugs in the treatment of hypertension. Arch. intern. Med.133, 1017 (1974)
Mikkelsen, E.O., Bengtsson, B., Andersson, K.-E.: Effects of verapamil and nitroglycerin on contractile responses to potassium and noradrenaline in isolated human peripheral veins. Acta Pharmacol. Toxiol. In pres. (1978)
Nayler, W.G., McInnes, I., Swann, J.B., Price, J.M., Cardon, V., Race, D., Lowe, T.W.: Some effects of iproveratril (Isoptin) on the cardiovascular system. J. Pharm. exp. Ther.161, 247 (1968)
Rydén, L., Saetre, H.: The haemodynamic effect of verapamil. Europ. J. clin. Pharmacol.3, 153 (1971)
Tarazi, R.C., Dustan, H.P., Bravo, E.L., Niarchos, A.P.: Vasodilating drugs: contrasting haemodynamic effects. Clin. Sci. mol. Med.51, 575s (1976)
Thulesius, O., Lim, B.H., Gjöres, J.E.: Peripheral vascular actions of verapamil in man. Symposium on Arrhythmias. Isoptin. Göteborg 1974. (Ed. J.H. Atterhög, A. Haakana and B. Nordling) p. 73. Aulendorf: Editio Cantor 1974
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pedersen, O.L. Does verapamil have a clinically significant antihypertensive effect?. Eur J Clin Pharmacol 13, 21–24 (1978). https://doi.org/10.1007/BF00606677
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00606677